Literature DB >> 19943802

A high dose of IMT504, the PyNTTTTGT prototype immunostimulatory oligonucleotide, does not alter embryonic development in rats.

Andrés Hernando-Insúa1, Juan M Rodriguez, Fernanda Elías, Juan Fló, Ricardo López, Raul Franco, Nestor Lago, Jorge Zorzopulos, Alejandro D Montaner.   

Abstract

Synthetic oligodeoxynucleotides (ODNs) are currently being evaluated as vaccine adjuvants for inducing protective immunity. As maternal vaccination is becoming increasingly common, the potential risk of vaccine formulation using ODN adjuvants should be warranted. A recent study performed in mice suggests that exposure to CpG motifs during pregnancy could result (although at very high doses as compared to the ones proposed for human vaccination) in fetal loss and morphological defects. PyNTTTTGT ODNs are immunostimulatory ODNs not bearing CpG motifs, which are very efficient vaccine adjuvants. In this report, we analyzed the potential teratogenic effect of its prototype IMT504 in rats. This animal model was chosen because PyNTTTTGT ODNs are barely active in mice. Intraperitoneal injection of IMT504 at a dose of 20 mg/kg (more than 1000 times higher than the one proposed for a vaccine dose in humans) at day 6 of pregnancy did not produce a significant decrease in the mean number of implanted fetuses or in the number of live pups delivered. Neither the fetuses nor the offspring presented malformations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19943802     DOI: 10.1089/oli.2009.0206

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  4 in total

1.  The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis.

Authors:  Abdullah Chahin; Steven M Opal; Jorge Zorzopulos; David V Jobes; Yazan Migdady; Michelle Yamamoto; Nicholas Parejo; John E Palardy; David L Horn
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

Review 2.  Maternal vaccination: moving the science forward.

Authors:  Azure N Faucette; Benjamin L Unger; Bernard Gonik; Kang Chen
Journal:  Hum Reprod Update       Date:  2014-07-11       Impact factor: 15.610

3.  Non-clinical safety studies of IMT504, a unique non-CpG oligonucleotide.

Authors:  Raúl Franco; Juan M Rodriguez; Fernanda Elías; Andrés Hernando-Insúa; Juan Fló; Ricardo López; Carlos Nagle; Néstor Lago; Jorge Zorzopulos; David L Horn; Alejandro D Montaner
Journal:  Nucleic Acid Ther       Date:  2014-04-10       Impact factor: 5.486

Review 4.  Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy.

Authors:  Jorge Zorzopulos; Steven M Opal; Andrés Hernando-Insúa; Juan M Rodriguez; Fernanda Elías; Juan Fló; Ricardo A López; Norma A Chasseing; Victoria A Lux-Lantos; Maria F Coronel; Raul Franco; Alejandro D Montaner; David L Horn
Journal:  World J Stem Cells       Date:  2017-03-26       Impact factor: 5.326

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.